SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Martek Biosciences---- future biotech cash cow!

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: richardred who wrote (234)12/21/2005 12:15:19 AM
From: richardred  Read Replies (1) of 258
 
Lonza acquires DHA-business from Nutrinova, a subsidiary of Celanese Corporation

Lonza has acquired Nutrinova’s DHA business including know-how, patents and registrations in the major global markets. DHA (Docosahexaenoic acid) is a fermentation based health ingredient derived entirely from natural microalgae. It is one of the most important Omega-3 polyunsaturated fatty acids. Numerous scientific as well as clinical studies have demonstrated positive health effects of DHA in particular, in the areas of heart health and brain function. Due to its vegetarian source and superior sensory properties relative to fish oil, DHA has broad applications in the dietary supplements, functional foods and beverages and speciality sectors. Nutrinova DHA has suceesfully been introduced in numerous foods and supplements around the world during the past two years.

With the acquisition of DHA, Lonza expands its portfolio of nutrition businesses within Organic Fine & Performance Chemicals with a health ingredient already well recognized by educated consumer groups. The proprietary fermentation technology of the acquired DHA business provides exclusive access to a unique production strain. Lonza’s process development excellence and manufacturing expertise combined with the ability to become a leading provider of DHA will significantly enhance the value of this business for our customers.

The DHA-business is synergistic with the current L-Carnitine and Niacin franchises of Lonza and will further strengthen the existing distribution channels worldwide. With this acquisition a first important strategy milestone has been completed.

Nutrinova’s superior DHA technology, talented workforce and experience in biotechnology and the food & beverage and health care markets make it an excellent complement.

About Lonza
Lonza, a chemical and biotechnology company driven by the life sciences, generated sales of CHF 2.18 billion in 2004. Headquartered in Switzerland, Lonza operates 18 production and R&D sites around the world. Its 5700 employees are passionately committed to delivering sustainable value to their customers. Lonza is one of the leading custom manufacturers of chemical intermediates, active ingredients and biopharmaceuticals for the pharmaceutical and agrochemical industries. On the basis of organic chemical, oleochemical and biotechnology platforms, Lonza creates value-added solutions for the nutrition, hygiene & personal care, wood & water treatment and industrial specialty markets. Lonza also offers polymer intermediates, resins and compounds. Further information can be found on our website www.lonza.com.

About Nutrinova
Nutrinova, a subsidiary of Celanese Corporation, is a globally operating supplier of food ingredients and specialtlies for the food, beverage and pharmaceutical industry. With more than 243 employees, more than a dozen affiliates and a strong sales network in all major markets, Nutrinova is a leading expert and partner for sweetening and food protection. Further information can be found on our website www.nutrinova.com.

For further information:
Assigned for Media Relations
Christine Menz
Tel +41 61 316 8253
Fax +41 61 316 9253
christine.menz@lonza.com

Investor Relations
Laura Gerber
Tel +41 61 316 8347
Fax +41 61 316 8220
laura.gerber@lonza.com

lonza.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext